GlassScriptPhysician profile
Bradley J Abrams
NPI 1316901895
$8,594.09
in general payments reported to CMS, 2019-2025
33 companies · $703 in 2025
The $703 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $975 · 2021: $2,257 · 2022: $1,956 · 2023: $1,040 · 2024: $970 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $3,133.61 | 2020-2025 | |
| Abbvie INC. | $849.89 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $578.67 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $401.77 | 2019-2025 | Ilumya |
| Janssen Biotech, INC. | $371.72 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $314.31 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $305.85 | 2021-2025 | Dupixent |
| Ucb, INC. | $290.69 | 2021-2025 | Bimzelx, Cimzia |
| Biofrontera INC. | $272.83 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Incyte Corporation | $231.97 | 2021-2025 | Opzelura |
| Genzyme Corporation | $210.39 | 2020-2024 | |
| Leo Pharma INC. | $208.53 | 2019-2023 | Adbry |
| Organogenesis INC. | $198.27 | 2021-2024 | Affinity |
| Lilly USA, LLC | $159.01 | 2020-2022 | |
| Strata Skin Sciences, INC. | $124.89 | 2021-2024 | Xtrac |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $120.54 | 2019 | |
| Dermavant Sciences, INC. | $105.64 | 2022-2024 | Vtama |
| Allergan, INC. | $84.56 | 2019-2021 | |
| Galderma Laboratories, L.P. | $81.88 | 2020-2025 | Nemluvio |
| Sandoz INC. | $76.32 | 2019-2020 | |
| Pfizer INC. | $72.87 | 2021-2022 | |
| Convatec INC. | $62.99 | 2024-2025 | |
| Vyne Pharmaceuticals INC. | $59.25 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.64 | 2022-2024 | Spevigo |
| Genentech USA, INC. | $41.93 | 2024 | Xolair, Erivedge |
| Almirall LLC | $39.60 | 2021-2025 | Seysara |
| E.R. Squibb & Sons, L.L.C. | $27.25 | 2024 | Sotyktu |
| Paratek Pharmaceuticals, INC. | $23.72 | 2022 | |
| Celgene Corporation | $23.16 | 2019 | |
| Smith+Nephew, INC. | $20.66 | 2024 | Grafix Pl |
| Lifenet Health | $20.40 | 2023 | |
| Aclaris Therapeutics, INC. | $17.39 | 2019 | |
| Next Science LLC | $12.89 | 2023 | Xperience, Surgx, Blastx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.